Research programme: antibacterial viruses - Novolytics
Alternative Names: Antibacterial viruses research programme - Novolytics; Bacteriophages research programme - Novolytics; Research programme: bacteriophages - NovolyticsLatest Information Update: 14 May 2019
At a glance
- Originator Novolytics
- Class Viruses
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Methicillin-resistant Staphylococcus aureus infections
Most Recent Events
- 09 May 2019 C3J Therapeutics has merged with AmpliPhi Biosciences Corporation to form Armata Pharmaceuticals
- 16 Jul 2016 No recent reports of development identified for preclinical development in Methicillin-resistant-Staphylococcus-aureus-infections in United Kingdom (Intranasal, Cream)
- 04 Sep 2003 This product is available for co-development (http://www.novolytics.co.uk)